Activity of garenoxacin against macrolide-susceptible and -resistant Mycoplasma pneumoniae [1]

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 6, 2007, Pages 2278-2279

  Yamazaki, Tsutomu ^a   Sasaki, Tsuguo ^b   Takahata, Masahiro ^c  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c TOYAMA CHEMICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; GARENOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MINOCYCLINE; MOXIFLOXACIN;

ANTIBIOTIC SENSITIVITY; DRUG ACTIVITY; DRUG SENSITIVITY; HUMAN; LETTER; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; MYCOPLASMA PNEUMONIAE;

EID: 34250187417     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01561-06     Document Type: Letter

References (13)

1. Douthwaite, S., L. H. Hansen, and P. Mauvais. 2000. Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA. Mol. Microbiol. 36:183-193.
2. Gruson, D., S. Pereyre, H. Renaudin, A. Charron, C. Bebear, and C. M. Bebear. 2005. In vitro development of resistance to six and four fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, respectively. Antimicrob. Agents Chemother. 49:1190-1193.
3. Kenny, G. E., and F. D. Cartwright. 2001. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob. Agents Chemother. 45:2604-2608.
4. Langtry, H. D., and J. A. Balfour. 1998. Azithromycin. A review of its use in pediatric infectious diseases. Drugs 56:273-297.
5. Lucier, T. S., K. Heitzman, S. K. Liu, and P. C. Hu. 1995. Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 39:2770-2773.
6. Matsuoka, M., M. Narita, N. Okazaki, H. Ohya, T. Yamazaki, K. Ouchi, I. Suzuki, T. Andoh, T. Kenri, Y. Sasaki, A. Horino, M. Shintani, Y. Arakawa, and T. Sasaki. 2004. Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob. Agents Chemother. 48:4624-4630.
7. Okazaki, N., M. Narita, S. Yamada, K. Izumikawa, M. Umetsu, K. Kenri, Y. Sasaki, Y. Arakawa, and T. Sasaki. 2001. Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol. Immunol. 45:617-620.
8. Pereyre, S., H. Renaudin, C. Bebear, and C. M. Bebear. 2004. In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas. Antimicrob. Agents Chemother. 48:3165-3168.
9. Suzuki, S., T. Yamazaki, M. Narita, N. Okazaki, I. Suzuki, T. Andoh, M. Matsuoka, T. Kenri, Y. Arakawa, and T. Sasaki. 2006. Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 50:709-712.
10. Takahata, M., J. Mitsuyama, Y. Yamashiro, M. Yonezawa, H. Araki, Y. Todo, S. Minami, Y. Watanabe, and H. Narita. 1999. In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrob. Agents Chemother. 43:1077-1084.
11. Taylor-Robinson, D., and C. J. Bebear. 1997. Antibiotic susceptibilities of mycoplasmas and treatment of mycoplasmal infections. J. Antimicrob. Chemother. 40:622-630.
12. Waites, K. B., D. M. Crabb, X. Bing, and L. B. Duffy. 2003. In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrob. Agents Chemother. 47:161-165.
13. Weisblum, B. 1995. Erythromycin resistance by ribosome modification. Antimicrob. Agents Chemother. 39:577-585.